IRMD Stock Analysis: Iradimed | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 1.085m USD | 12M Return: 17.6% | US46266A1097 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 11.6M
EPS Trend: 97.6%
Qual. Beats: 0
Rev. Trend: 99.7%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
IRADIMED CORPORATION (IRMD) is a small-cap healthcare equipment company that develops, manufactures, markets, and distributes MRI-compatible medical devices, including intravenous infusion pump systems, patient vital signs monitoring systems, and ferromagnetic detection devices. Its product portfolio features proprietary items such as the MRidium 3870 and 3860+ IV infusion pumps, the 3880 vital signs monitor, and the 3600 FMD1 ferromagnetic detection device, supported by a range of non-magnetic accessories and consumables like disposable IV tubing sets and SpO2 sensors.
The company sells its products to hospitals, acute care facilities, and outpatient imaging centers, using a hybrid sales model that combines direct field representatives, regional sales directors, and clinical application specialists with independent distributors across U.S. and international markets. Founded in 1992 and headquartered in Orlando, Florida, IRADIMED has been publicly traded on NASDAQ since its 2014 IPO. The company operates in a specialized niche within the broader medical device industry, addressing safety challenges unique to MRI environments where conventional electronic equipment cannot be used due to magnetic interference.
- MRI procedure volumes drive infusion pump orders
- Niche MRI-compatible portfolio sustains premium gross margins
- International distributor growth diversifies US hospital revenue
| Net Income: 23.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.22 > 0.02 and ΔFCF/TA 8.95 > 1.0 |
| NWC/Revenue: 89.83% < 20% (prev 88.31%; Δ 1.52% < -1%) |
| CFO/TA 0.24 > 3% & CFO 27.1m > Net Income 23.1m |
| Net Debt/EBITDA: error (cannot be calculated) |
| Current Ratio: 9.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (12.9m) vs 12m ago 0.32% < -2% |
| Gross Margin: 75.86% > 18% (prev 76.96%; Δ -1.10% > 0.5%) |
| Asset Turnover: 77.99% > 50% (prev 72.93%; Δ 5.05% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.67 (Total Current Assets 86.7m - Total Current Liabilities 9.16m) / Total Assets 115.0m |
| B: 0.61 (Retained Earnings 70.2m / Total Assets 115.0m) |
| C: 0.26 (EBIT TTM 29.2m / Avg Total Assets 110.7m) |
| D: 7.69 (Book Value of Equity 101.7m / Total Liabilities 13.2m) |
| Altman-Z'' = 16.27 = AAA |
| DSRI: 1.09 (Receivables 13.2m/10.9m, Revenue 86.3m/77.6m) |
| GMI: 1.01 (GM 76.96% / 75.86%) |
| AQI: 0.61 (AQ_t 0.04 / AQ_t-1 0.06) |
| SGI: 1.11 (Revenue 86.3m / 77.6m) |
| TATA: -0.04 (NI 23.1m - CFO 27.1m) / TA 115.0m) |
| Beneish M = -3.10 (Cap -4..+1) = AA |
As of October 10, 2026, the stock is trading at USD 87.45 with a total of 68,873 shares traded. Over the past week, the price has changed by +2.40%, over one month by +4.66%, over three months by -10.60% and over the past year by +17.55%.
Current recommended Stop Loss: 84.60 (which is 3.3% or 1.3 ATR below the current price).
Iradimed has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy IRMD.
- StrongBuy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 118 | 34.9% |
P/E Trailing = 47.3855
P/E Forward = 41.1523
P/S = 12.5622
P/B = 10.8575
P/EG = 4.46
Revenue TTM = 86.3m USD
EBIT TTM = 29.2m USD
EBITDA TTM = 31.1m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.03b USD (1.08b + (null Debt) - CCE 59.1m)
Interest Coverage Ratio = unknown (Ebit TTM 29.2m / Interest Expense TTM 0.0)
EV/FCF = 41.13x (Enterprise Value 1.03b / FCF TTM 24.9m)
FCF Yield = 2.43% (FCF TTM 24.9m / Enterprise Value 1.03b)
FCF Margin = 28.88% (FCF TTM 24.9m / Revenue TTM 86.3m)
Net Margin = 26.70% (Net Income TTM 23.1m / Revenue TTM 86.3m)
Gross Margin = 75.86% ((Revenue TTM 86.3m - Cost of Revenue TTM 20.8m) / Revenue TTM)
Gross Margin QoQ = 74.07% (prev 76.50%)
Tobins Q-Ratio = 8.92 (Enterprise Value 1.03b / Total Assets 115.0m)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 22.49% (6.69m / 29.7m)
NOPAT = 22.7m (EBIT 29.2m * (1 - 22.49%))
Current Ratio = 9.46 (Total Current Assets 86.7m / Total Current Liabilities 9.16m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 31.1m)
Debt / FCF = unknown (Net Debt none / FCF TTM 24.9m)
Total Stockholder Equity = 98.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 20.82% (Net Income 23.1m / Total Assets 115.0m)
RoE = 23.45% (Net Income TTM 23.1m / Total Stockholder Equity 98.3m)
RoCE = 27.64% (EBIT 29.2m / Capital Employed (Total Assets 115.0m - Current Liab 9.16m))
RoIC = 22.34% (NOPAT 22.7m / Invested Capital 101.5m)
WACC = 7.01% (E(1.08b)/V(1.08b) * Re(7.01%) + (debt-free company))
Discount Rate = 7.01% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.96 | Cagr: 0.42%
[DCF] Terminal Value 77.97% ; FCFF base≈20.4m ; Y1≈23.4m ; Y5≈34.4m
[DCF] Fair Price = 40.46 (EV 517.4m - Net Debt 0.0 = Equity 517.4m / Shares 12.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 97.62 | EPS CAGR: 12.42% | SUE: -0.40 | # QB: 0
Revenue Correlation: 99.68 | Revenue CAGR: 12.55% | SUE: 0.35 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.55 | Chg30d=+0.92% | Revisions=+25% | Analysts=3
EPS current Year (2026-12-31): EPS=2.11 | Chg30d=+1.11% | Revisions=+40% | GrowthEPS=+9.5% | GrowthRev=+9.8%
EPS next Year (2027-12-31): EPS=2.45 | Chg30d=+1.80% | Revisions=+40% | GrowthEPS=+16.1% | GrowthRev=+13.1%
[Analyst] Revisions Ratio: +62% (up=5, down=0)